Association of ACE I/D polymorphism with blood pressure response to valsartan-hydrochlorothiazide combination therapy in hypertensive patients from Khyber Pakhtunkhwa, Pakistan [0.03%]
巴基斯坦开伯尔普赫图赫瓦省高血压患者血管紧张素转换酶插入/删除多态性与缬沙坦氢氯噻嗪联合治疗血压反应关联的研究
Aftab Ullah,Abdur Rahim,Asif Jan et al.
Aftab Ullah et al.
Background: Interindividual variability in antihypertensive response may be partly explained by genetic variation. The angiotensin-converting enzyme insertion/deletion polymorphism (ACE I/D; rs1799752) has been associated...
Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis [0.03%]
NAT2慢代谢与结核病治疗毒性作用的系统评价和meta分析
Sofia Dinegro,Sara Dal Molin,Ilaria Mariani et al.
Sofia Dinegro et al.
Introduction: Adverse drug reactions (ADRs) remain a major challenge in tuberculosis treatment and frequently compromise therapeutic adherence and outcomes. Hepatotoxicity represents the most clinically significant toxici...
Evaluation of dopamine transporter gene variations in Turkish children with attention deficit hyperactivity disorder treated with methylphenidate adverse effects [0.03%]
多巴胺转运蛋白基因变异与土耳其注意缺陷多动障碍患儿甲基苯丙胺不良反应的相关性研究
Kubra Cigdem Pekkoc-Uyanik,Melik Yigit Bayindir,Muhammet Fatih Akdemir et al.
Kubra Cigdem Pekkoc-Uyanik et al.
Aim: Attention-deficit hyperactivity disorder (ADHD) is a common childhood psychiatric disorder, with methylphenidate (MPH) as the first-line treatment. MPH primarily exerts its effects by inhibiting the dopamine transpor...
Polygenic risk score and risk of drug-induced liver injury after initiating antiretroviral therapy in people living with HIV [0.03%]
人类免疫缺陷病毒感染者的多基因风险评分与开始抗逆转录病毒治疗后的药物性肝损伤风险的关系研究
Zinhle Cindi,Katie M Cardone,Yuki Bradford et al.
Zinhle Cindi et al.
Introduction: Drug-induced liver injury affects some people living with HIV (PWH) during antiretroviral therapy (ART). We examined associations of polygenic risk scores (PRS) with liver injury during ART. ...
Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial [0.03%]
儿童癌症护理中遵循国际药物基因组学建议的依从性：来自MARVEL-PIC随机试验的队列分析
Aniket Chawla,Sean Carter,Roxanne Dyas et al.
Aniket Chawla et al.
Background: Pharmacogenomic (PGx) testing can optimize drug efficacy and minimize toxicity, but prescriber adherence to PGx recommendations remains unclear. We aimed to quantify clinician adherence to international PGx re...
Closely similar tacrolimus morning troughs and graft function across the recipients' common ABCB1 polymorphisms (c.2677G>T/A, c.1236C>T, c.3435C>T) early after renal transplantation [0.03%]
肾移植早期同种异体ABCB1多态性（c.2677G>T / A，c.1236C>T，c.3435C>T）受者中的他克莫司早晨谷浓度和移植物功能的密切相关性
Luka Penezić,Sandra Nađ Škegro,Lana Ganoci et al.
Luka Penezić et al.
Background: Reports about relevance of three common and linked ABCB1 polymorphisms (c.2677G>T/A, c.1236C>T, c.3435C>T) for exposure to- and functional outcomes in tacrolimus-treated renal transplant patients are inconsist...
Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use [0.03%]
用于抑郁症分层抗抑郁治疗的药物基因组学：证据、局限性和临床应用路线图
Bernhard T Baune
Bernhard T Baune
Major depressive disorder (MDD) is treated largely by trial and error, despite marked interindividual variation in antidepressant exposure, efficacy and tolerability. Pharmacogenomics (PGx) has therefore been proposed as a route to stratifi...
Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type" [0.03%]
知情公众关于采集和分享抑郁症药物基因组学检测结果的指导意见：“这与你的血型没有区别”
Colene Bentley,Louisa Edwards,Kieran C O&#x;Doherty et al.
Colene Bentley et al.
Introduction: Many people with major depressive disorder (MDD) undergo a lengthy process of trial-and-error before finding a medication that works well for them. Pharmacogenomic (PGx) testing for MDD can help find a suita...
Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models [0.03%]
临床服务输送模型下的药物基因组学流程优化：定性评估
Emily Huang,Aniwaa Owusu Obeng,Scott A Stuart et al.
Emily Huang et al.
Despite the promise of personalized medicine, the clinical implementation of pharmacogenomics (PGx) remains limited. Several barriers limiting implementation of PGx have been identified, some of which include provider awareness, uncertainty...
Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases [0.03%]
单基因预测与人工智能驱动的多基因精确诊疗在心血管疾病中的联合应用
Navakanth Raju Ramayanam,Sarad Pawar Naik Bukke,Chandrashekar Thalluri et al.
Navakanth Raju Ramayanam et al.
Pharmacogenomics (PGx) is transforming how we treat cardiovascular disease (CVD) by enabling us to select and dose drugs based on our genetic profiles. The pharmacokinetics and pharmacodynamics of commonly prescribed cardiovascular drugs ar...